Precision BioSciences (NASDAQ:DTIL) Trading Up 3.6% – Time to Buy?

Precision BioSciences, Inc. (NASDAQ:DTIL)’s stock price was up 3.6% during mid-day trading on Thursday . The company traded as high as $7.17 and last traded at $7.11. Approximately 77,368 shares were traded during trading, a decline of 2% from the average daily volume of 79,007 shares. The stock had previously closed at $6.86.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of Precision BioSciences in a research note on Thursday, August 22nd.

Precision BioSciences Price Performance

The company has a current ratio of 9.22, a quick ratio of 9.22 and a debt-to-equity ratio of 0.34. The company has a 50 day moving average of $8.45 and a 200-day moving average of $9.74. The firm has a market capitalization of $54.54 million, a P/E ratio of 118.50 and a beta of 1.71.

Hedge Funds Weigh In On Precision BioSciences

An institutional investor recently bought a new position in Precision BioSciences stock. Janus Henderson Group PLC bought a new stake in Precision BioSciences, Inc. (NASDAQ:DTIL) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 573,052 shares of the company’s stock, valued at approximately $7,739,000. Janus Henderson Group PLC owned approximately 8.29% of Precision BioSciences at the end of the most recent quarter. 37.99% of the stock is owned by institutional investors.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.